MedAlliance Swiss Medical Technology

MedAlliance Swiss Medical Technology is a privately-owned medical technology company headquartered in Nyon, Switzerland, specializing in the development and commercialization of innovative drug-eluting balloon (DEB) technologies for the treatment of coronary and peripheral artery disease.

Founded in 2008, MedAlliance has dedicated itself to pioneering solutions for patients suffering from life-threatening cardiovascular conditions. We leverage breakthrough proprietary technology, including our unique MicroReservoirs made from biodegradable polymer intermixed with the anti-restenotic drug sirolimus, to deliver sustained drug release and improve patient outcomes.

MedAlliance’s commitment to innovation is exemplified by its receipt of Breakthrough Device Designation Status from the US FDA for its SELUTION SLR coronary DEB, and subsequent CE Mark approvals for both coronary and peripheral indications. Our CAT technology further enhances these solutions, providing a secure and effective method for balloon delivery. We are a global company with operations spanning Europe, North America, and Asia, dedicated to advancing cardiovascular care.